Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

Abstract Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel...

Full description

Saved in:

Bibliographic Details
Published in:	Thrombosis and haemostasis Vol. 120; no. 7; pp. 1004 - 1024
Main Authors:	Bikdeli, Behnood, Madhavan, Mahesh V., Gupta, Aakriti, Jimenez, David, Burton, John R., Der Nigoghossian, Caroline, Chuich, Taylor, Nouri, Shayan Nabavi, Dreyfus, Isaac, Driggin, Elissa, Sethi, Sanjum, Sehgal, Kartik, Chatterjee, Saurav, Ageno, Walter, Madjid, Mohammad, Guo, Yutao, Tang, Liang V., Hu, Yu, Bertoletti, Laurent, Giri, Jay, Cushman, Mary, Quéré, Isabelle, Dimakakos, Evangelos P., Gibson, C. Michael, Lippi, Giuseppe, Favaloro, Emmanuel J., Fareed, Jawed, Tafur, Alfonso J., Francese, Dominic P., Batra, Jaya, Falanga, Anna, Clerkin, Kevin J., Uriel, Nir, Kirtane, Ajay, McLintock, Claire, Hunt, Beverley J., Spyropoulos, Alex C., Barnes, Geoffrey D., Eikelboom, John W., Weinberg, Ido, Schulman, Sam, Carrier, Marc, Piazza, Gregory, Beckman, Joshua A., Leon, Martin B., Stone, Gregg W., Rosenkranz, Stephan, Goldhaber, Samuel Z., Parikh, Sahil A., Monreal, Manuel, Krumholz, Harlan M., Konstantinides, Stavros V., Weitz, Jeffrey I., Lip, Gregory Y. H.
Format:	Journal Article
Language:	English
Published:	Stuttgart · New York Georg Thieme Verlag KG 01.07.2020
Subjects:	Animals Anti-Inflammatory Agents - therapeutic use Anticoagulants - therapeutic use Antiviral Agents - therapeutic use Betacoronavirus Coronavirus Infections - complications Coronavirus Infections - drug therapy Coronavirus Infections - immunology COVID-19 COVID-19 Drug Treatment Fibrinolytic Agents - therapeutic use Glycosaminoglycans - therapeutic use Hemostasis Humans Inflammation - complications Inflammation - drug therapy Inflammation - immunology Pandemics Platelet Aggregation Inhibitors - therapeutic use Pneumonia, Viral - complications Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Review Article SARS-CoV-2 Thrombosis - complications Thrombosis - drug therapy Thrombosis - immunology immunomodulator thrombosis inflammation coronavirus disease 2019 anticoagulation thrombomodulin fibrinolytic therapy antithrombin
ISSN:	0340-6245, 2567-689X, 2567-689X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0340-6245 2567-689X 2567-689X
DOI:	10.1055/s-0040-1713152